OmniAb (NASDAQ:OABI) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$4.17m (down 24% from 3Q 2023).
- Net loss: US$16.4m (loss widened by 4.0% from 3Q 2023).
- US$0.16 loss per share (further deteriorated from US$0.16 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
OmniAb Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 50%. Earnings per share (EPS) also missed analyst estimates by 16%.
Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 12% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for OmniAb you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:OABI
OmniAb
A biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States.
Excellent balance sheet and slightly overvalued.
